As the UAE medical device market continues to grow, many overseas manufacturers are seeking guidance on UAE medical device registration and regulatory compliance. One of the most misunderstood aspects of the UAE regulatory framework is Article 22 of Federal Decree-Law No. 38 of 2024 Governing Medical Products, Pharmacists and Pharmaceutical Establishments.
Many international manufacturers mistakenly believe that:
A single importer is sufficient for UAE market access
Product registration is always the first regulatory step
One local entity can manage the entire UAE import and distribution structure
However, the UAE regulatory framework is more comprehensive. Manufacturers must carefully plan importer appointments, regulatory responsibilities, and market-entry strategies before initiating UAE medical device registration activities.
What Does Article 22 Require?
Article 22 establishes specific obligations for Marketing Right Holders entering the UAE market.
Under the legislation, the Marketing Right Holder must appoint:
At least two Emirates Drug Establishment (EDE)-licensed pharmaceutical establishments as importers
One or more licensed pharmaceutical establishments for distribution activities
One designated main pharmaceutical establishment responsible for regulatory oversight
The designated main establishment is responsible for:
Product licensing activities
Pharmacovigilance obligations
Lifecycle management of the medical product
Regulatory communication with the Emirates Drug Establishment (EDE)
The regulation also confirms that:
Only one unified marketing approval application is submitted for each medical product
Multiple importers may operate under the same regulatory framework
All appointed importers are expected to conduct import activities during the calendar year
Exemptions may be granted by the UAE Cabinet under specific circumstances
Why Article 22 Matters for UAE Medical Device Registration
For manufacturers pursuing UAE medical device registration, Article 22 is not simply an administrative requirement.
The provision is designed to strengthen:
Supply chain continuity
Regulatory oversight
Product lifecycle management
Pharmacovigilance compliance
Market availability of medical products within the UAE
Failure to properly structure importer appointments can create delays during registration and market-entry planning.
Common Compliance Mistakes Made by Medical Device Manufacturers
Manufacturers entering the UAE frequently encounter compliance challenges, including:
1. Assuming One Importer Is Sufficient
Article 22 generally requires the appointment of at least two licensed pharmaceutical establishments as importers.
2. Prioritizing Registration Before Regulatory Structure
Many companies begin preparing registration dossiers before establishing a compliant importer framework. In practice, importer designation and regulatory responsibilities should be addressed early in the planning process.
3. Overlooking Lifecycle Management Requirements
The designated main pharmaceutical establishment is responsible for ongoing regulatory obligations beyond initial registration, including pharmacovigilance and product lifecycle management.
How OMC Supports Article 22 Compliance
Complying with Article 22 requires more than appointing importers—it requires a structured regulatory strategy aligned with UAE market-entry requirements.
OMC Medical supports international manufacturers with UAE medical device registration, importer coordination, and regulatory compliance under Federal Decree-Law No. 38 of 2024. Through its UAE operational and partnership structure, OMC helps manufacturers establish compliant importer arrangements and navigate EDE requirements efficiently.
Our support includes:
Article 22 compliance planning
Dual importer coordination
UAE medical device registration support
Regulatory submissions and licensing assistance
Lifecycle management and ongoing compliance
By working with OMC, manufacturers can streamline their UAE market-entry process while building a compliant and sustainable regulatory framework.
Ready to Enter the UAE Market?
Need guidance on Article 22 compliance or UAE medical device registration?
Contact OMC Medical today to discuss your UAE market-entry strategy and regulatory requirements.
Conclusion
Article 22 of UAE Federal Decree-Law No. 38 of 2024 plays a critical role in UAE medical device compliance and market access.
Manufacturers seeking UAE medical device registration should understand:
The requirement to appoint at least two licensed importers
The role of the designated main pharmaceutical establishment
Pharmacovigilance and lifecycle management obligations
Importer coordination requirements for ongoing compliance
Developing the correct regulatory structure from the outset can significantly improve registration efficiency and reduce compliance risks during UAE market entry.
